Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated August 8, 2025, discloses insider trading activity in compliance with Article 19 of Regulation No. 596/2014 on market abuse. The filing covers a transaction executed on August 7, 2025, by an executive of the company, a global healthcare leader headquartered in Denmark focused on chronic diseases.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a regulatory disclosure of a specific share transaction.
| Metric | Value |
|---|---|
| Transaction Type | Sale of Shares |
| Instrument | Novo Nordisk B Shares (DK0062498333) |
| Volume | 28,710 shares |
| Price per Share | DKK 295.00 |
| Total Value | DKK 8,469,450.00 |
| Transaction Date | August 7, 2025 |
| Exchange | Nasdaq Copenhagen |
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It solely reports a reduction in shareholding by an executive.
Guidance, Outlook, and Risks
The filing contains no management guidance, future outlook, risk factors, or discussion of contingencies. It is a routine disclosure of a transaction by Ludovic Helfgott, Executive Vice President.
Key Facts for Investor Verification
- Insider Identity: The seller is Ludovic Helfgott, Executive Vice President.
- Transaction Nature: A sale of 28,710 B shares at DKK 295.00 per share.
- Timing: The transaction occurred on August 7, 2025, one day prior to the filing date.
- Market Context: The trade was executed on Nasdaq Copenhagen, not the NYSE (where ADRs trade).
- Financial Impact: The filing does not provide data on the executive's remaining holdings or the company's overall financial health.